Free Trial
→ Trump wipes out trillions overnight… (From Porter & Company) (Ad) Buy AXSM Stock  Free AXSM Stock Alerts

Axsome Therapeutics (AXSM) Financials

Axsome Therapeutics logo
$102.99 -0.99 (-0.95%)
Closing price 05/28/2025 04:00 PM Eastern
Extended Trading
$103.00 +0.01 (+0.01%)
As of 05/28/2025 07:35 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Axsome Therapeutics

Annual Income Statements for Axsome Therapeutics

This table shows Axsome Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Income / (Loss) Attributable to Common Shareholders		 -287 -239 -187 -130 -103 -68 -31 -29 -27 -12
Consolidated Net Income / (Loss)		 -287 -239 -187 -130 -103 -68 -31 -29 -27 -12
Net Income / (Loss) Continuing Operations		 -287 -239 -187 -130 -103 -68 -31 -29 -27 -12
Total Pre-Tax Income 		-287 -238 -187 -130 -103 -68 -31 -29 -28 -12
Total Operating Income		 -281 -232 -180 -125 -99 -67 -33 -27 -28 -9.20
Total Gross Profit		 352 245 45 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Revenue		 386 271 50 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Revenue		 386 271 50 0.00 0.00 - - - - -
Total Cost of Revenue		 33 26 5.20 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cost of Revenue		 33 26 5.20 0.00 0.00 - - - - -
Total Operating Expenses		 633 476 225 125 99 67 33 27 28 9.20
Selling, General & Admin Expense		 411 323 159 67 29 14 9.35 7.21 6.34 2.42
Research & Development Expense		 187 98 58 58 70 54 23 20 21 6.78
Amortization Expense		 6.39 6.38 4.14 0.00 0.00 - - - - -
Other Operating Expenses / (Income)		 28 49 3.30 0.00 0.00 - - - - -
Total Other Income / (Expense), net		 -6.57 -6.45 -7.34 -5.70 -3.81 -1.24 1.66 -1.99 -0.13 -3.29
Interest & Investment Income		 -6.57 -6.45 -7.34 -5.70 -2.57 -1.24 -1.13 -1.34 -0.13 -0.74
Income Tax Expense		 0.09 0.96 0.00 0.00 -0.05 - -0.22 - - -
Other Gains / (Losses), net		 0.00 0.00 0.00 0.00 - 0.14 - 0.21 0.47 0.00
Basic Earnings per Share		 ($5.99) ($5.27) ($4.60) ($3.47) ($2.77) ($2.01) ($1.15) ($1.27) ($1.42) ($1.02)
Weighted Average Basic Shares Outstanding		 47.91M 45.43M 40.66M 37.62M 37.21M 34.02M 26.88M 22.76M 19.15M 11.95M
Diluted Earnings per Share		 ($5.99) ($5.27) ($4.60) ($3.47) ($2.77) ($2.01) ($1.15) ($1.27) ($1.42) ($1.02)
Weighted Average Diluted Shares Outstanding		 47.91M 45.43M 40.66M 37.62M 37.21M 34.02M 26.88M 22.76M 19.15M 11.95M
Weighted Average Basic & Diluted Shares Outstanding		 48.77M 47.37M 43.52M 37.62M 37.21M 34.02M 26.88M 22.76M 19.15M 11.95M

Quarterly Income Statements for Axsome Therapeutics

This table shows Axsome Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Income / (Loss) Attributable to Common Shareholders		 -59 -75 -65 -79 -68 -99 -62 -67 -11 -61 -45
Consolidated Net Income / (Loss)		 -59 -75 -65 -79 -68 -99 -62 -67 -11 -61 -45
Net Income / (Loss) Continuing Operations		 -59 -75 -65 -79 -68 -99 -62 -67 -11 -61 -45
Total Pre-Tax Income 		-59 -75 -65 -79 -68 -99 -63 -68 -8.64 -61 -45
Total Operating Income		 -57 -73 -63 -78 -67 -98 -62 -65 -6.37 -60 -42
Total Gross Profit		 112 108 96 79 69 64 51 42 87 22 15
Total Revenue		 121 119 105 87 75 72 58 47 95 24 17
Operating Revenue		 121 119 105 87 75 72 58 47 95 24 17
Total Cost of Revenue		 9.79 11 8.44 8.06 6.30 7.38 6.53 4.60 7.56 2.29 1.92
Operating Cost of Revenue		 9.79 11 8.44 8.06 6.30 7.38 6.53 4.60 7.56 2.29 1.92
Total Operating Expenses		 169 181 159 157 136 162 113 107 93 82 57
Selling, General & Admin Expense		 121 113 96 104 99 87 83 79 74 61 41
Research & Development Expense		 45 55 45 50 37 31 29 21 18 15 15
Amortization Expense		 1.57 1.61 1.61 1.59 1.59 1.61 1.61 1.59 1.57 1.61 1.61
Other Operating Expenses / (Income)		 1.51 11 16 2.16 -1.41 43 -0.18 6.05 -0.16 4.20 -0.04
Total Other Income / (Expense), net		 -2.43 -2.21 -1.98 -1.30 -1.08 -0.70 -0.76 -2.73 -2.26 -1.32 -2.41
Interest & Investment Income		 -2.43 -2.21 -1.98 -1.30 -1.08 -0.70 -0.76 -2.73 -2.26 -1.32 -2.41
Income Tax Expense		 0.00 0.09 0.00 0.00 0.00 -0.33 -0.68 -0.62 2.58 - 0.00
Basic Earnings per Share		 ($1.22) ($1.54) ($1.34) ($1.67) ($1.44) ($2.15) ($1.32) ($1.54) ($0.26) ($1.44) ($1.07)
Weighted Average Basic Shares Outstanding		 48.87M 47.91M 48.14M 47.57M 47.39M 45.43M 47.12M 43.67M 43.52M 40.66M 41.70M
Diluted Earnings per Share		 ($1.22) ($1.54) ($1.34) ($1.67) ($1.44) ($2.15) ($1.32) ($1.54) ($0.26) ($1.44) ($1.07)
Weighted Average Diluted Shares Outstanding		 48.87M 47.91M 48.14M 47.57M 47.39M 45.43M 47.12M 43.67M 43.52M 40.66M 41.70M
Weighted Average Basic & Diluted Shares Outstanding		 49.24M 48.77M 48.46M 48.00M 47.50M 47.37M 47.32M 47.19M 43.57M 43.52M 43.43M

Annual Cash Flow Statements for Axsome Therapeutics

This table details how cash moves in and out of Axsome Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Net Change in Cash & Equivalents		 -71 185 114 -97 -36 206 -20 -2.60 -11 45
Net Cash From Operating Activities		 -128 -145 -117 -108 -78 -46 -30 -26 -21 -7.44
Net Cash From Continuing Operating Activities		 -128 -145 -117 -108 -78 -46 -30 -26 -21 -7.44
Net Income / (Loss) Continuing Operations		 -287 -239 -187 -130 -103 -68 -31 -29 -27 -12
Consolidated Net Income / (Loss)		 -287 -239 -187 -130 -103 -68 -31 -29 -27 -12
Depreciation Expense		 0.53 0.46 0.26 0.08 0.02 0.04 0.05 0.04 0.02 0.00
Amortization Expense		 10 8.95 5.62 1.08 0.84 0.65 0.38 0.47 0.07 0.05
Non-Cash Adjustments To Reconcile Net Income		 114 113 41 21 23 6.12 -1.04 2.72 2.03 3.78
Changes in Operating Assets and Liabilities, net		 34 -28 24 0.32 0.41 15 1.52 -0.81 3.80 0.94
Net Cash From Investing Activities		 -0.27 -0.58 -54 -0.31 -0.05 -0.02 -0.03 -0.01 -0.10 -0.02
Net Cash From Continuing Investing Activities		 -0.27 -0.58 -54 -0.31 -0.05 -0.02 -0.03 -0.01 -0.10 -0.02
Purchase of Property, Plant & Equipment		 -0.27 -0.58 -0.70 -0.31 -0.05 -0.02 -0.03 -0.01 -0.10 -0.02
Acquisitions		 0.00 0.00 -53 0.00 0.00 - - - - -
Net Cash From Financing Activities		 58 331 285 11 42 252 10 24 9.97 53
Net Cash From Continuing Financing Activities		 58 331 285 11 42 252 10 24 9.97 53
Repayment of Debt		 0.00 -1.44 -0.49 -0.31 -23 -7.24 -3.36 -0.28 -0.06 0.00
Repurchase of Common Equity		 -0.82 -16 -6.98 -0.22 - 0.00 - - - -
Issuance of Debt		 0.00 85 45 0.00 50 20 0.00 0.00 10 7.44
Issuance of Common Equity		 71 259 250 7.44 14 238 13 24 0.00 46
Other Financing Activities, net		 -13 4.37 -2.97 4.23 1.05 1.39 0.51 0.48 0.03 0.00
Cash Interest Paid		 20 17 7.69 4.63 2.10 1.29 0.77 0.87 0.05 -

Quarterly Cash Flow Statements for Axsome Therapeutics

This table details how cash moves in and out of Axsome Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Net Change in Cash & Equivalents		 -14 -12 12 -16 -55 -30 -21 191 46 -27 154
Net Cash From Operating Activities		 -43 -26 -19 -30 -53 -30 -54 -55 -5.82 -28 -23
Net Cash From Continuing Operating Activities		 -43 -26 -19 -30 -53 -30 -54 -55 -5.82 -28 -23
Net Income / (Loss) Continuing Operations		 -59 -75 -65 -79 -68 -99 -62 -67 -11 -61 -45
Consolidated Net Income / (Loss)		 -59 -75 -65 -79 -68 -99 -62 -67 -11 -61 -45
Depreciation Expense		 0.15 0.13 0.13 0.14 0.13 0.13 0.14 0.10 0.09 0.09 0.07
Amortization Expense		 2.65 2.65 2.60 2.49 2.32 2.06 2.23 2.50 2.16 1.95 2.06
Non-Cash Adjustments To Reconcile Net Income		 23 33 38 24 19 63 15 23 13 15 8.67
Changes in Operating Assets and Liabilities, net		 -10 13 5.08 23 -6.81 3.43 -8.66 -14 -9.63 17 11
Net Cash From Investing Activities		 -0.34 -0.03 -0.09 -0.05 -0.10 -0.01 -0.37 -0.13 -0.07 -0.18 -0.07
Net Cash From Continuing Investing Activities		 -0.34 -0.03 -0.09 -0.05 -0.10 -0.01 -0.37 -0.13 -0.07 -0.18 -0.07
Purchase of Property, Plant & Equipment		 -0.34 -0.03 -0.09 -0.05 -0.10 -0.01 -0.37 -0.13 -0.07 -0.18 -0.07
Net Cash From Financing Activities		 29 14 30 14 -1.19 -0.00 33 246 52 1.07 177
Net Cash From Continuing Financing Activities		 29 14 30 14 -1.19 -0.00 33 246 52 1.07 177
Repurchase of Common Equity		 -0.39 -0.33 -0.26 - - - -2.05 - - - -5.22
Issuance of Common Equity		 20 18 43 - - -11 45 - - 6.25 180
Other Financing Activities, net		 10 -2.99 -12 3.34 -1.19 10 -8.75 4.93 -2.22 -5.19 1.97
Cash Interest Paid		 4.59 4.76 5.02 5.01 4.90 4.87 4.73 3.92 3.22 2.57 2.53

Annual Balance Sheets for Axsome Therapeutics

This table presents Axsome Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Total Assets		 568 588 331 88 186 221 15 36 38 49
Total Current Assets		 485 504 246 87 184 220 15 35 38 49
Cash & Equivalents		 315 386 201 86 184 220 14 34 37 48
Accounts Receivable		 142 95 38 0.00 - - - - - -
Inventories, net		 16 15 4.32 0.00 - - - - - -
Prepaid Expenses		 12 8.12 2.78 0.05 0.15 0.41 1.25 1.28 1.38 1.00
Plant, Property, & Equipment, net		 0.58 0.85 0.72 0.28 0.05 0.03 0.05 0.07 0.10 0.02
Total Noncurrent Assets		 83 83 85 0.98 2.06 0.14 0.11 0.19 0.11 0.03
Goodwill		 12 12 10 0.00 - - - - - -
Intangible Assets		 47 53 60 0.00 - - - - - -
Other Noncurrent Operating Assets		 24 18 15 0.98 2.06 0.14 0.11 0.19 0.11 0.03
Total Liabilities & Shareholders' Equity		 568 588 331 88 186 221 15 36 38 49
Total Liabilities		 511 397 222 72 72 42 14 19 17 2.63
Total Current Liabilities		 230 139 97 23 23 24 11 12 7.17 2.63
Short-Term Debt		 8.29 6.41 5.90 0.00 - 2.60 3.29 3.27 0.27 0.00
Accounts Payable		 220 131 90 22 22 22 7.53 6.11 6.90 2.63
Other Current Liabilities		 1.84 1.27 0.43 0.62 1.22 0.00 - 2.79 0.00 -
Total Noncurrent Liabilities		 281 258 125 49 49 17 3.62 6.66 9.47 0.00
Long-Term Debt		 181 178 94 49 48 17 3.62 6.66 9.47 0.00
Capital Lease Obligations		 2.94 0.00 - - - - - - - -
Other Noncurrent Operating Liabilities		 98 80 31 0.00 0.58 0.00 - - - -
Total Equity & Noncontrolling Interests		 57 191 110 16 114 179 0.94 17 22 46
Total Preferred & Common Equity		 57 191 110 16 114 179 0.94 17 22 46
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 - -
Total Common Equity		 57 191 110 16 114 179 0.94 17 22 46
Common Stock		 1,180 1,027 706 425 393 355 108 93 69 67
Retained Earnings		 -1,123 -836 -596 -409 -279 -176 -108 -77 -48 -20

Quarterly Balance Sheets for Axsome Therapeutics

This table presents Axsome Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2025 Q3 2024 Q2 2024 Q1 2024 Q3 2023 Q2 2023 Q1 2023 Q3 2022
Period end date 3/31/2025 9/30/2024 6/30/2024 3/31/2024 9/30/2023 6/30/2023 3/31/2023 9/30/2022
Total Assets		 597 561 548 546 601 612 389 339
Total Current Assets		 495 479 463 460 512 520 304 252
Cash & Equivalents		 301 327 316 331 417 437 247 228
Accounts Receivable		 161 124 120 101 78 67 45 20
Inventories, net		 16 14 15 16 9.99 9.25 7.94 2.10
Prepaid Expenses		 16 13 12 12 6.80 5.91 5.20 2.46
Plant, Property, & Equipment, net		 0.77 0.68 0.72 0.81 0.97 0.74 0.70 0.63
Total Noncurrent Assets		 101 82 84 84 88 91 84 86
Goodwill		 12 12 12 12 12 12 10 12
Intangible Assets		 45 49 50 52 55 57 58 61
Other Noncurrent Operating Assets		 44 21 22 21 21 23 16 13
Total Liabilities & Shareholders' Equity		 597 561 548 546 601 612 389 339
Total Liabilities		 543 469 445 402 331 333 277 182
Total Current Liabilities		 244 196 187 144 115 115 101 60
Short-Term Debt		 8.60 8.13 7.04 6.39 6.67 6.34 6.00 7.00
Accounts Payable		 235 186 178 137 108 108 95 53
Other Current Liabilities		 0.45 1.63 1.42 1.15 0.44 0.35 0.11 0.42
Total Noncurrent Liabilities		 300 272 259 258 217 218 177 121
Long-Term Debt		 181 180 179 179 177 177 148 94
Capital Lease Obligations		 3.68 2.95 3.03 1.70 - - - -
Other Noncurrent Operating Liabilities		 114 89 76 77 39 41 29 27
Total Equity & Noncontrolling Interests		 53 93 103 144 270 279 112 157
Total Preferred & Common Equity		 53 93 103 144 270 279 112 157
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 53 93 103 144 270 279 112 157
Common Stock		 1,235 1,141 1,086 1,048 1,006 954 719 692
Retained Earnings		 -1,182 -1,048 -983 -904 -737 -675 -608 -535

Annual Metrics And Ratios for Axsome Therapeutics

This table displays calculated financial ratios and metrics derived from Axsome Therapeutics' official financial filings.

Metric 2024 2023 2022 2021 2020 2019 2018 2017 2016 2015
Period end date 12/31/2024 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019 12/31/2018 12/31/2017 12/31/2016 12/31/2015
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 42.53% 440.80% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -21.38% -27.89% -40.76% -25.72% -47.66% -124.62% -8.55% 0.57% -196.76% -12.35%
EBIT Growth		 -21.02% -28.94% -44.18% -25.79% -47.43% -123.74% -8.07% -0.97% -196.01% -62.41%
NOPAT Growth		 -21.02% -28.94% -44.18% -25.79% -47.43% -104.72% -20.92% 1.38% -199.51% -62.13%
Net Income Growth		 -20.05% -27.84% -43.50% -26.73% -50.56% -120.71% -6.99% -6.40% -122.77% -103.49%
EPS Growth		 -13.66% -14.57% -32.56% -25.27% -37.81% -74.78% 9.45% 10.56% -39.22% -54.55%
Operating Cash Flow Growth		 11.49% -24.52% -7.66% -37.94% -69.18% -54.31% -13.53% -24.39% -186.08% -61.84%
Free Cash Flow Firm Growth		 1.36% 8.83% -79.24% -26.63% -116.25% -31.51% -43.03% -8.90% -221.23% 0.00%
Invested Capital Growth		 -518.31% -221.03% 140.79% 0.04% -2.13% -248.18% 16.98% -38.89% -233.38% 0.00%
Revenue Q/Q Growth		 13.96% 21.11% 94.95% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 8.86% -20.74% -17.24% -26.71% 15.47% -28.81% 0.00% 0.00% -18.57% 0.00%
EBIT Q/Q Growth		 8.38% -19.83% -17.91% -26.33% 15.23% -28.66% 0.00% 0.00% -18.89% 0.00%
NOPAT Q/Q Growth		 8.38% -19.83% -17.91% -26.33% 15.23% -28.66% 0.00% 0.00% -19.38% 0.00%
Net Income Q/Q Growth		 7.63% -18.54% -17.05% -24.83% 14.01% -28.63% 0.00% 0.00% -17.06% 0.00%
EPS Q/Q Growth		 9.24% -15.57% -13.30% -3.27% -2.59% -24.07% 0.00% 0.00% -10.94% 0.00%
Operating Cash Flow Q/Q Growth		 3.14% -1.97% 1.08% -8.29% -3.96% -20.14% -13.19% 3.38% -30.44% 0.00%
Free Cash Flow Firm Q/Q Growth		 -5.08% -0.66% 2.34% -33.41% 13.66% 0.00% 0.00% 0.00% 0.00% 0.00%
Invested Capital Q/Q Growth		 -53.14% -128.98% -71.15% 4.30% -14.10% -24.89% 0.00% 0.00% 6.97% 0.00%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 91.37% 90.37% 89.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 -69.99% -82.19% -347.57% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 -72.74% -85.67% -359.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 -72.74% -85.67% -359.33% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 -74.47% -88.41% -373.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 100.03% 100.40% 100.00% 100.00% 99.95% 99.80% 99.30% 99.29% 98.29% 97.80%
Interest Burden Percent		 102.34% 102.78% 104.08% 104.57% 103.85% 101.84% 103.75% 104.82% 100.48% 134.18%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -231.63% -159.21% -298.97% -201.51% -70.36% -76.08% -350.78% -151.19% -79.99% -26.29%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% -1,763.61% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 -48.51% -50.41% -85.77% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 -49.66% -52.02% -89.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 -231.63% -159.21% -298.97% -201.51% -70.36% -76.08% -350.78% -151.19% -79.99% -26.29%
Return on Equity Simple (ROE_SIMPLE)		 -503.76% -125.27% -170.81% -834.29% -90.43% -38.24% -3,301.50% -173.14% -126.10% -26.29%
Net Operating Profit after Tax (NOPAT)		 -196 -162 -126 -87 -69 -47 -23 -19 -19 -6.44
NOPAT Margin		 -50.92% -59.97% -251.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -55.87% -50.90% -88.76% -49.85% -19.97% -20.55% -51.20% -38.96% -21.15% -24.04%
Return On Investment Capital (ROIC_SIMPLE)		 -78.89% -43.22% -60.01% - - - - - - -
Cost of Revenue to Revenue		 8.63% 9.63% 10.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 106.65% 119.41% 318.27% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 48.50% 36.20% 115.81% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 164.11% 176.04% 448.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -281 -232 -180 -125 -99 -67 -30 -28 -28 -9.30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -270 -222 -174 -124 -98 -67 -30 -27 -27 -9.25
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 71.92 19.72 30.57 91.10 26.74 19.96 89.64 7.93 5.99 0.00
Price to Tangible Book Value (P/TBV)		 0.00 29.97 84.61 91.10 26.74 19.96 89.64 7.93 5.99 0.00
Price to Revenue (P/Rev)		 10.63 13.92 66.94 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 366.14 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 10.31 13.17 64.93 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 3.37 0.97 0.91 3.14 0.42 0.11 7.37 0.59 0.45 0.00
Long-Term Debt to Equity		 3.22 0.93 0.86 3.14 0.42 0.10 3.86 0.40 0.44 0.00
Financial Leverage		 -1.31 -1.01 -1.10 -1.34 -1.15 -1.15 -1.76 -1.33 -1.10 -1.03
Leverage Ratio		 4.66 3.06 3.35 2.12 1.39 1.31 2.89 1.93 1.28 1.06
Compound Leverage Factor		 4.77 3.15 3.49 2.21 1.44 1.34 2.99 2.02 1.29 1.42
Debt to Total Capital		 77.10% 49.13% 47.76% 75.85% 29.81% 10.03% 88.05% 37.27% 31.11% 0.00%
Short-Term Debt to Total Capital		 3.33% 1.71% 2.81% 0.00% 0.00% 1.31% 41.94% 12.27% 0.86% 0.00%
Long-Term Debt to Total Capital		 73.77% 47.43% 44.95% 75.85% 29.81% 8.72% 46.11% 25.00% 30.25% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 22.90% 50.87% 52.24% 24.15% 70.19% 89.97% 11.95% 62.73% 68.89% 100.00%
Debt to EBITDA		 -0.71 -0.83 -0.58 -0.40 -0.49 -0.30 -0.23 -0.36 -0.35 0.00
Net Debt to EBITDA		 0.46 0.91 0.58 0.30 1.38 3.01 0.24 0.88 0.98 0.00
Long-Term Debt to EBITDA		 -0.68 -0.80 -0.54 -0.40 -0.49 -0.26 -0.12 -0.24 -0.35 0.00
Debt to NOPAT		 -0.98 -1.14 -0.80 -0.56 -0.70 -0.42 -0.30 -0.52 -0.51 0.00
Net Debt to NOPAT		 0.63 1.24 0.80 0.43 1.95 4.25 0.31 1.27 1.39 0.00
Long-Term Debt to NOPAT		 -0.94 -1.10 -0.75 -0.56 -0.70 -0.37 -0.16 -0.35 -0.49 0.00
Altman Z-Score		 1.63 3.60 5.44 1.49 22.41 50.11 -12.40 -0.59 1.51 0.00
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 2.11 3.63 2.54 3.75 7.85 9.00 1.41 2.90 5.30 18.63
Quick Ratio		 1.99 3.46 2.47 3.75 7.85 8.98 1.29 2.79 5.11 18.25
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -141 -143 -156 -87 -69 -32 -24 -17 -16 -4.85
Operating Cash Flow to CapEx		 -47,559.26% -24,927.84% -16,597.01% -35,138.31% -170,962.87% -287,668.62% -91,918.59% -267,444.45% -20,353.00% -36,835.81%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 -55.29 0.00 0.00 0.00 0.00 -1.98
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 -62.92 0.00 0.00 0.00 0.00 -3.04
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -62.95 0.00 0.00 0.00 0.00 -3.05
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.67 0.59 0.24 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 3.26 4.08 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 2.16 2.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 539.43 345.15 99.49 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Accounts Payable Turnover		 0.19 0.24 0.09 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 112.06 89.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 169.15 136.22 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 1,924.37 1,550.29 3,956.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 -1,643.17 -1,324.70 -3,956.17 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -66 -11 8.87 -22 -22 -21 -6.12 -7.37 -5.31 -1.59
Invested Capital Turnover		 -10.00 -290.03 -7.77 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Increase / (Decrease) in Invested Capital		 -56 -20 31 0.01 -0.45 -15 1.25 -2.06 -3.72 -1.59
Enterprise Value (EV)		 3,977 3,564 3,249 1,387 2,907 3,367 77 108 102 0.00
Market Capitalization		 4,100 3,766 3,349 1,424 3,042 3,567 84 133 129 0.00
Book Value per Share		 $1.18 $4.04 $2.52 $0.41 $3.06 $5.18 $0.03 $0.71 $1.13 $3.89
Tangible Book Value per Share		 ($0.04) $2.66 $0.91 $0.41 $3.06 $5.18 $0.03 $0.71 $1.13 $3.89
Total Capital		 249 375 210 65 162 199 7.85 27 31 46
Total Debt		 192 184 100 49 48 20 6.91 9.93 9.74 0.00
Total Long-Term Debt		 184 178 94 49 48 17 3.62 6.66 9.47 0.00
Net Debt		 -123 -202 -101 -37 -136 -200 -7.06 -24 -27 -48
Capital Expenditures (CapEx)		 0.27 0.58 0.70 0.31 0.05 0.02 0.03 0.01 0.10 0.02
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -52 -14 -46 -23 -23 -21 -6.28 -7.63 -5.52 -1.64
Debt-free Net Working Capital (DFNWC)		 263 372 155 63 161 198 7.68 26 31 46
Net Working Capital (NWC)		 255 365 149 63 161 196 4.39 23 31 46
Net Nonoperating Expense (NNE)		 91 77 61 43 34 21 7.97 9.93 7.92 5.77
Net Nonoperating Obligations (NNO)		 -123 -202 -101 -37 -136 -200 -7.06 -24 -27 -48
Total Depreciation and Amortization (D&A)		 11 9.41 5.89 1.15 0.86 0.69 0.42 0.51 0.09 0.05
Debt-free, Cash-free Net Working Capital to Revenue		 -13.51% -5.31% -91.65% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt-free Net Working Capital to Revenue		 68.25% 137.40% 309.73% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Working Capital to Revenue		 66.10% 135.04% 297.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($5.99) ($5.27) ($4.60) ($3.47) ($2.77) ($2.01) ($1.15) ($1.27) ($1.42) ($1.02)
Adjusted Weighted Average Basic Shares Outstanding		 47.91M 45.43M 40.66M 38.48M 37.41M 37.08M 33.28M 25.49M 19.20M 11.95M
Adjusted Diluted Earnings per Share		 ($5.99) ($5.27) ($4.60) ($3.47) ($2.77) ($2.01) ($1.15) ($1.27) ($1.42) ($1.02)
Adjusted Weighted Average Diluted Shares Outstanding		 47.91M 45.43M 40.66M 38.48M 37.41M 37.08M 33.28M 25.49M 19.20M 11.95M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 ($3.47) ($2.77) ($2.01) ($1.15) ($1.27) ($1.42) ($1.02)
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 48.77M 47.37M 43.52M 37.62M 37.21M 34.02M 26.88M 22.76M 19.15M 11.95M
Normalized Net Operating Profit after Tax (NOPAT)		 -196 -162 -126 -87 -69 -47 -23 -19 -19 -6.44
Normalized NOPAT Margin		 -50.92% -59.97% -251.53% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 -74.45% -88.06% -373.99% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 -79.50 0.00 0.00 0.00 0.00 -3.81
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 -55.65 0.00 0.00 0.00 0.00 -2.63
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -79.54 0.00 0.00 0.00 0.00 -3.81
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 -55.69 0.00 0.00 0.00 0.00 -2.64
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.28% -6.55% -3.73% -0.17% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Axsome Therapeutics

This table displays calculated financial ratios and metrics derived from Axsome Therapeutics' official financial filings.

Metric Q1 2025 Q4 2024 Q3 2024 Q2 2024 Q1 2024 Q4 2023 Q3 2023 Q2 2023 Q1 2023 Q4 2022 Q3 2022
Period end date 3/31/2025 12/31/2024 9/30/2024 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023 3/31/2023 12/31/2022 9/30/2022
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 61.95% 66.04% 81.27% 86.65% -20.70% 193.50% 243.07% 429.48% 0.00% 0.00% 0.00%
EBITDA Growth		 16.42% 27.31% -0.24% -20.74% -1,470.37% -66.00% -48.34% -64.35% 89.07% -79.17% -19.63%
EBIT Growth		 15.30% 26.11% -0.81% -19.97% -955.46% -64.02% -46.47% -66.04% 83.35% -83.75% -26.95%
NOPAT Growth		 15.30% 26.11% -0.81% -19.97% -955.46% -64.02% -46.47% -66.04% 83.35% -83.75% -26.95%
Net Income Growth		 13.08% 24.06% -3.86% -18.13% -509.35% -61.09% -38.77% -62.10% 71.69% -80.25% -28.50%
EPS Growth		 15.28% 28.37% -1.52% -8.44% -453.85% -49.31% -23.36% -45.28% 74.76% -60.00% -15.05%
Operating Cash Flow Growth		 18.88% 13.70% 65.21% 45.60% -818.52% -10.15% -135.29% -65.04% 82.17% 4.43% 15.01%
Free Cash Flow Firm Growth		 149.10% 109.82% 173.47% 78.17% 37.49% 32.23% 40.14% 67.41% -70.33% -217.80% -321.64%
Invested Capital Growth		 -8,465.13% -518.31% -216.99% -194.19% -103.34% -221.03% 20.51% -39.70% 191.38% 140.79% 235.29%
Revenue Q/Q Growth		 2.27% 13.37% 20.19% 16.22% 4.85% 23.77% 23.76% -50.62% 288.07% 44.67% 91.00%
EBITDA Q/Q Growth		 22.42% -16.61% 20.58% -16.33% 32.53% -60.80% 4.34% -1,413.06% 92.87% -43.70% -5.99%
EBIT Q/Q Growth		 21.53% -15.96% 19.76% -16.01% 31.54% -58.20% 4.51% -920.66% 89.36% -41.27% -8.25%
NOPAT Q/Q Growth		 21.53% -15.96% 19.76% -16.01% 31.54% -58.20% 4.51% -920.66% 89.36% -41.27% -8.25%
Net Income Q/Q Growth		 20.69% -15.96% 18.58% -16.07% 30.71% -58.61% 7.40% -498.77% 81.68% -36.63% -8.17%
EPS Q/Q Growth		 20.78% -14.93% 19.76% -15.97% 33.02% -62.88% 14.29% -492.31% 81.94% -34.58% -0.94%
Operating Cash Flow Q/Q Growth		 -65.54% -40.64% 38.12% 43.68% -76.10% 43.30% 3.25% -850.85% 78.88% -21.11% 32.14%
Free Cash Flow Firm Q/Q Growth		 180.13% -86.80% 674.39% 76.88% 43.98% 1.23% -70.64% 33.79% 39.27% 12.75% 7.11%
Invested Capital Q/Q Growth		 18.61% -53.14% -85.22% -3,609.98% 94.12% -128.98% 49.12% 31.41% 113.14% -71.15% -25.38%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 91.94% 91.15% 91.95% 90.76% 91.60% 89.69% 88.70% 90.15% 92.01% 90.60% 88.58%
EBITDA Margin		 -44.61% -58.80% -57.17% -86.52% -86.43% -134.32% -103.38% -133.75% -4.36% -237.49% -239.10%
Operating Margin		 -46.91% -61.14% -59.78% -89.54% -89.70% -137.39% -107.49% -139.31% -6.74% -245.85% -251.76%
EBIT Margin		 -46.91% -61.14% -59.78% -89.54% -89.70% -137.39% -107.49% -139.31% -6.74% -245.85% -251.76%
Profit (Net Income) Margin		 -48.91% -63.08% -61.67% -91.03% -91.14% -137.92% -107.62% -143.83% -11.86% -251.29% -266.08%
Tax Burden Percent		 100.00% 100.11% 100.00% 100.00% 100.00% 99.67% 98.92% 99.09% 129.87% 100.00% 100.00%
Interest Burden Percent		 104.27% 103.04% 103.16% 101.66% 101.61% 100.71% 101.22% 104.20% 135.52% 102.21% 105.68%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -25,321.38% -1,724.41% 0.00% -495.80% -538.73% 0.00% 0.00% -1,127.57%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -25,308.38% -1,706.51% 0.00% -485.37% -519.75% 0.00% 0.00% -1,111.81%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 25,212.69% 1,584.57% 0.00% 408.26% 402.95% 0.00% 0.00% 1,067.23%
Return on Equity (ROE)		 -282.16% -231.63% -171.61% -108.69% -139.84% -159.21% -87.54% -135.77% -250.92% -298.97% -60.34%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -418.00% -318.68% -756.81% -1,763.61% -521.00%
Operating Return on Assets (OROA)		 -35.49% -40.77% -34.81% -45.00% -48.17% -80.85% -51.11% -64.18% -4.08% -58.68% -28.37%
Return on Assets (ROA)		 -37.01% -42.06% -35.91% -45.75% -48.94% -81.16% -51.17% -66.27% -7.18% -59.98% -29.98%
Return on Common Equity (ROCE)		 -282.16% -231.63% -171.61% -108.69% -139.84% -159.21% -87.54% -135.77% -250.92% -298.97% -60.34%
Return on Equity Simple (ROE_SIMPLE)		 -523.02% 0.00% -334.73% -300.00% -205.77% 0.00% -74.89% -66.16% -141.95% 0.00% -101.59%
Net Operating Profit after Tax (NOPAT)		 -40 -51 -44 -55 -47 -69 -43 -46 -4.46 -42 -30
NOPAT Margin		 -32.84% -42.80% -41.84% -62.68% -62.79% -96.17% -75.24% -97.52% -4.72% -172.10% -176.23%
Net Nonoperating Expense Percent (NNEP)		 -15.50% -14.81% -11.26% -13.00% -17.90% -19.75% -10.42% -18.98% -10.53% -27.96% -15.76%
Return On Investment Capital (ROIC_SIMPLE)		 -16.16% -20.42% - - - -18.32% - - - -20.00% -
Cost of Revenue to Revenue		 8.06% 8.85% 8.05% 9.24% 8.40% 10.31% 11.30% 9.85% 7.99% 9.40% 11.42%
SG&A Expenses to Revenue		 99.44% 95.37% 91.22% 118.80% 131.96% 121.36% 143.94% 169.03% 78.45% 252.34% 242.74%
R&D to Revenue		 36.87% 46.31% 43.32% 57.19% 49.11% 43.06% 49.78% 44.07% 18.81% 60.29% 88.31%
Operating Expenses to Revenue		 138.85% 152.29% 151.72% 180.30% 181.31% 227.07% 196.18% 229.46% 98.75% 336.45% 340.34%
Earnings before Interest and Taxes (EBIT)		 -57 -73 -63 -78 -67 -98 -62 -65 -6.37 -60 -42
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -54 -70 -60 -75 -65 -96 -60 -62 -4.13 -58 -40
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 106.90 71.92 46.44 37.17 26.22 19.72 12.24 11.23 24.01 30.57 11.43
Price to Tangible Book Value (P/TBV)		 0.00 0.00 133.33 93.93 47.03 29.97 16.28 14.89 61.83 84.61 21.36
Price to Revenue (P/Rev)		 13.16 10.63 12.75 13.12 15.04 13.92 14.76 17.16 18.56 66.94 70.07
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 0.00 0.00 0.00 82.72 115.77 137.01 366.14 54.36
Enterprise Value to Revenue (EV/Rev)		 12.91 10.31 12.34 12.68 14.47 13.17 13.72 15.77 17.92 64.93 65.14
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 3.64 3.37 2.06 1.84 1.30 0.97 0.68 0.66 1.37 0.91 0.64
Long-Term Debt to Equity		 3.48 3.22 1.97 1.77 1.25 0.93 0.66 0.63 1.32 0.86 0.60
Financial Leverage		 -1.28 -1.31 -1.02 -1.00 -0.93 -1.01 -0.84 -0.78 -1.01 -1.10 -0.96
Leverage Ratio		 5.79 4.66 3.21 3.04 3.65 3.06 2.20 2.69 3.78 3.35 2.28
Compound Leverage Factor		 6.04 4.81 3.31 3.09 3.71 3.08 2.23 2.81 5.12 3.42 2.41
Debt to Total Capital		 78.45% 77.10% 67.29% 64.81% 56.46% 49.13% 40.59% 39.65% 57.87% 47.76% 39.07%
Short-Term Debt to Total Capital		 3.48% 3.33% 2.86% 2.41% 1.93% 1.71% 1.47% 1.37% 2.26% 2.81% 2.71%
Long-Term Debt to Total Capital		 74.96% 73.77% 64.42% 62.40% 54.53% 47.43% 39.12% 38.28% 55.61% 44.95% 36.36%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 21.55% 22.90% 32.71% 35.19% 43.54% 50.87% 59.41% 60.35% 42.13% 52.24% 60.93%
Debt to EBITDA		 -0.75 -0.71 -0.65 -0.64 -0.66 -0.83 -1.00 -1.11 -1.10 -0.58 -0.68
Net Debt to EBITDA		 0.41 0.46 0.46 0.43 0.51 0.91 1.26 1.54 0.66 0.58 0.85
Long-Term Debt to EBITDA		 -0.71 -0.68 -0.62 -0.62 -0.64 -0.80 -0.96 -1.07 -1.05 -0.54 -0.63
Debt to NOPAT		 -1.02 -0.98 -0.89 -0.89 -0.91 -1.14 -1.36 -1.51 -1.48 -0.80 -0.95
Net Debt to NOPAT		 0.57 0.63 0.64 0.59 0.71 1.24 1.72 2.09 0.90 0.80 1.19
Long-Term Debt to NOPAT		 -0.98 -0.94 -0.85 -0.85 -0.88 -1.10 -1.31 -1.45 -1.43 -0.75 -0.88
Altman Z-Score		 4.42 2.84 3.75 3.31 4.07 4.35 5.08 4.84 4.57 6.63 4.07
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 2.03 2.11 2.44 2.48 3.20 3.63 4.46 4.52 3.02 2.54 4.19
Quick Ratio		 1.90 1.99 2.30 2.34 3.01 3.46 4.32 4.39 2.89 2.47 4.11
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 14 4.83 37 -6.37 -28 -49 -50 -29 -44 -73 -83
Operating Cash Flow to CapEx		 -12,832.84% -87,340.00% -20,701.11% -57,903.85% -54,558.16% -433,742.86% -14,433.42% -41,615.79% -8,198.59% -15,228.18% -34,481.82%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.76 0.67 0.58 0.50 0.54 0.59 0.48 0.46 0.61 0.24 0.11
Accounts Receivable Turnover		 3.29 3.26 3.34 3.11 3.43 4.08 4.53 4.37 0.00 0.00 0.00
Inventory Turnover		 2.31 2.16 2.49 2.31 2.11 2.68 3.47 1.67 0.00 0.00 0.00
Fixed Asset Turnover		 545.31 539.43 409.26 399.30 331.38 345.15 279.65 266.29 248.49 99.49 54.50
Accounts Payable Turnover		 0.20 0.19 0.21 0.20 0.21 0.24 0.26 0.23 0.22 0.09 0.08
Days Sales Outstanding (DSO)		 110.99 112.06 109.20 117.55 106.31 89.37 80.63 83.58 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 158.23 169.15 146.70 158.03 173.06 136.22 105.16 218.24 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 1,841.94 1,924.37 1,778.48 1,849.36 1,699.86 1,550.29 1,395.57 1,607.53 1,690.30 3,956.17 4,814.76
Cash Conversion Cycle (CCC)		 -1,572.71 -1,643.17 -1,522.58 -1,573.79 -1,420.49 -1,324.70 -1,209.78 -1,305.71 -1,690.30 -3,956.17 -4,814.76
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -54 -66 -43 -23 -0.63 -11 37 25 19 8.87 31
Invested Capital Turnover		 -15.81 -10.00 -107.50 404.00 27.46 -290.03 6.59 5.52 -162.02 -7.77 6.40
Increase / (Decrease) in Invested Capital		 -53 -56 -80 -48 -20 -20 6.31 -16 40 31 53
Enterprise Value (EV)		 5,580 3,977 4,178 3,697 3,631 3,564 3,066 2,877 2,591 3,249 1,672
Market Capitalization		 5,688 4,100 4,314 3,823 3,776 3,766 3,298 3,131 2,684 3,349 1,798
Book Value per Share		 $1.09 $1.18 $1.94 $2.17 $3.04 $4.04 $5.71 $6.40 $2.57 $2.52 $3.90
Tangible Book Value per Share		 ($0.09) ($0.04) $0.67 $0.86 $1.69 $2.66 $4.29 $4.83 $1.00 $0.91 $2.09
Total Capital		 247 249 284 292 331 375 454 462 265 210 258
Total Debt		 194 192 191 189 187 184 184 183 154 100 101
Total Long-Term Debt		 185 184 183 182 180 178 177 177 148 94 94
Net Debt		 -107 -123 -136 -126 -145 -202 -232 -254 -93 -101 -127
Capital Expenditures (CapEx)		 0.34 0.03 0.09 0.05 0.10 0.01 0.37 0.13 0.07 0.18 0.07
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -42 -52 -36 -32 -8.61 -14 -13 -26 -37 -46 -28
Debt-free Net Working Capital (DFNWC)		 259 263 291 283 323 372 404 411 210 155 199
Net Working Capital (NWC)		 251 255 283 276 316 365 397 405 204 149 192
Net Nonoperating Expense (NNE)		 20 24 21 25 21 30 19 22 6.76 19 15
Net Nonoperating Obligations (NNO)		 -107 -123 -136 -126 -145 -202 -232 -254 -93 -101 -127
Total Depreciation and Amortization (D&A)		 2.80 2.78 2.73 2.63 2.45 2.19 2.37 2.60 2.25 2.04 2.13
Debt-free, Cash-free Net Working Capital to Revenue		 -9.62% -13.51% -10.72% -11.03% -3.43% -5.31% -5.72% -14.28% -25.39% -91.65% -110.73%
Debt-free Net Working Capital to Revenue		 60.01% 68.25% 86.00% 97.26% 128.61% 137.40% 180.71% 225.24% 145.07% 309.73% 775.74%
Net Working Capital to Revenue		 58.02% 66.10% 83.59% 94.84% 126.06% 135.04% 177.72% 221.77% 140.93% 297.94% 748.46%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($1.22) ($1.54) ($1.34) ($1.67) ($1.44) ($2.15) ($1.32) ($1.54) ($0.26) ($1.44) ($1.07)
Adjusted Weighted Average Basic Shares Outstanding		 48.87M 47.91M 48.14M 47.57M 47.39M 45.43M 47.12M 43.67M 43.52M 40.66M 41.70M
Adjusted Diluted Earnings per Share		 ($1.22) ($1.54) ($1.34) ($1.67) ($1.44) ($2.15) ($1.32) ($1.54) ($0.26) ($1.44) ($1.07)
Adjusted Weighted Average Diluted Shares Outstanding		 48.87M 47.91M 48.14M 47.57M 47.39M 45.43M 47.12M 43.67M 43.52M 40.66M 41.70M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 49.24M 48.77M 48.46M 48.00M 47.50M 47.37M 47.32M 47.19M 43.57M 43.52M 43.43M
Normalized Net Operating Profit after Tax (NOPAT)		 -40 -51 -44 -55 -47 -69 -43 -46 -4.46 -42 -30
Normalized NOPAT Margin		 -32.84% -42.80% -41.84% -62.68% -62.79% -96.17% -75.24% -97.52% -4.72% -172.10% -176.23%
Pre Tax Income Margin		 -48.91% -63.00% -61.67% -91.03% -91.14% -138.37% -108.80% -145.15% -9.13% -251.29% -266.08%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 -0.43% -0.28% -0.16% -0.74% 0.00% -6.55% -7.76% -10.21% 0.00% -3.73% 0.00%

Frequently Asked Questions About Axsome Therapeutics' Financials

When does Axsome Therapeutics's fiscal year end?

According to the most recent income statement we have on file, Axsome Therapeutics' financial year ends in December. Their financial year 2024 ended on December 31, 2024.

How has Axsome Therapeutics' net income changed over the last 9 years?

Axsome Therapeutics' net income appears to be on an upward trend, with a most recent value of -$287.22 million in 2024, rising from -$12.21 million in 2015. The previous period was -$239.24 million in 2023. View Axsome Therapeutics' forecast to see where analysts expect Axsome Therapeutics to go next.

What is Axsome Therapeutics's operating income?
Axsome Therapeutics's total operating income in 2024 was -$280.56 million, based on the following breakdown:
  • Total Gross Profit: $352.39 million
  • Total Operating Expenses: $632.95 million
How has Axsome Therapeutics revenue changed over the last 9 years?

Over the last 9 years, Axsome Therapeutics' total revenue changed from $0.00 in 2015 to $385.69 million in 2024, a change of 38,569,300,000.0%.

How much debt does Axsome Therapeutics have?

Axsome Therapeutics' total liabilities were at $511.48 million at the end of 2024, a 28.8% increase from 2023, and a 19,334.0% increase since 2015.

How much cash does Axsome Therapeutics have?

In the past 9 years, Axsome Therapeutics' cash and equivalents has ranged from $13.97 million in 2018 to $386.19 million in 2023, and is currently $315.35 million as of their latest financial filing in 2024.

How has Axsome Therapeutics' book value per share changed over the last 9 years?

Over the last 9 years, Axsome Therapeutics' book value per share changed from 3.89 in 2015 to 1.18 in 2024, a change of -69.7%.


Related Companies

This page (NASDAQ:AXSM) was last updated on 5/29/2025 by MarketBeat.com Staff
From Our Partners
Market Panic: Trump Just Dropped a Bomb on Your Stocks
tock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...
American Alternative | Sponsored
White House to reset Social Security?
Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...
Altimetry | Sponsored
July 2025 Rule Change to Impact Retirement Investors
There's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...
Premier Gold Co | Sponsored
Is President Trump Lying To You With This?
President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...
Colonial Metals | Sponsored
A grave, grave error.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...
Porter & Company | Sponsored
Silicon Valley Gold Rush
A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...
Stansberry Research | Sponsored
Buffett’s favorite chart just hit 209% – here’s what that means for gold
A Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...
Golden Portfolio | Sponsored
Trump Exec Order 14179 is wealth “gift” to good Americans?
Is President Trump’s Executive Order 14179… A secret way to restore wealth for good citizens? If you’ve ...
Paradigm Press | Sponsored